Related Experiment Video
Updated: Jul 31, 2025
Mass Spectrometric Analysis of Glycosphingolipid Antigens
Published on: April 16, 2013
Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes
B Bishal Paudel1, Su-Fern Tan2, Todd E Fox3
1Department of Biomedical Engineering, University of Virginia, Charlottesville, VA.
Researchers identified two sphingolipid subtypes in acute myeloid leukemia (AML) based on hexosylceramide (Hex) and sphingomyelin (SM) levels. One subtype indicates poor prognosis and potential for novel sphingolipidomic therapies.
Area of Science:
- Biochemistry
- Oncology
- Genomics
Background:
- Acute myeloid leukemia (AML) exhibits complex, heterogeneous biology.
- Genomic classifications are established, but novel stratification methods are needed.
- Sphingolipids are bioactive molecules with potential roles in cancer.
Conclusions:
- Sphingolipid profiling offers a robust method for AML stratification beyond genomics.
- The identified high-risk subtype may not benefit from standard care, suggesting a need for targeted therapies.
- Sphingolipidomic interventions could offer new therapeutic strategies for AML patients.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
06:33Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023